There were two novel small molecules approved in April 2022:
- mavacamten (Camzyos), an oral cardiac myosin inhibitor
- oteseconazole (Vivjoy), an oral antifungal (jump to section)
This deep dive explores each drug in more detail, including the industry context, the clinical data, the target rationale, mechanisms of action, and drug origins.
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.
